October 25th 2024
Zanubrutinib, obinutuzumab, and venetoclax delivered promising response and survival data for the treatment of patients with mantle cell lymphoma harboring a TP53 mutation.
KTE-X19 Continues to Show Durable Efficacy in Relapsed/Refractory MCL
February 12th 2021After a minimum of 1 year of follow-up, patients with relapsed/refractory mantle cell lymphoma demonstrated substantial and durable clinical benefit and a manageable safety profile when receiving KTE-X19 chimeric antigen receptor T cell therapy.
Read More
New Chemotherapy-Free Option May Be Identified for Elderly Patients With MCL
February 5th 2021In an interview with Targeted Oncology, Preetesh Jain, MBBS, MD, DM, PhD, assistant professor, reviewed the results seen with ibrutinib added to rituximab in older patients with mantle cell lymphoma and provided insight on how to manage the interesting toxicity profile observed with the combination.
Read More
Less Aggressive Treatment Warranted for MCL With Primary GI Involvement
January 27th 2021Patients with mantle cell lymphoma and primary gastrointestinal involvement have similar outcomes to those with secondary gastrointestinal involvement, according to results from one of the largest known studies of gastrointestinal mantle cell lymphoma.
Read More
Parsaclisib Offers New Hope for Patients With BTK Inhibitor-Naïve Relapsed/Refractory MCL
January 7th 2021In an interview with Targeted Oncology, Amitkumar Mehta, MD, discussed the findings for the PI3Kδ inhibitor parsaclisib as treatment of patients with relapsed/refractory mantle cell lymphoma.
Read More
MCL35 Assay Stratifies Risk in Patients With Mantle Cell Lymphoma
December 21st 2020A new multi-analyte prognostic assay has demonstrated the potential to risk-stratifying patients with mantle cell lymphoma based on the particular molecular signature of an individual patient’s cancer, according to a new study.
Read More
Parsaclisib Leads to Significant ORR in R/R MCL Without Prior BTK Exposure
December 21st 2020Patients with relapsed or refractory mantle cell lymphoma treated with a daily dose of parsaclisib demonstrated significant activity and tolerability for the next-generation PI3Kδ inhibitor, according to findings from the phase 2 CITADEL-205 trial.
Read More
New Community-Setting Data Affirm Ibrutinib’s Efficacy in R/R MCL
November 25th 2020New data show patients with mantle cell lymphoma who were treated with ibrutinib in a community setting had similar outcomes to patients given the Bruton’s tyrosine kinase inhibitor in a clinical trial setting, a retrospective study showed.
Read More
Oncologists Highlight Major Unanswered Questions Remaining for Approved CAR T Treatment in MCL
November 24th 2020Investigators reported findings for 6 patients with mantle cell lymphoma who were treated in the ZUMA-2 clinical trial and progressed following treatment with therapy brexucabtagene autoleucel.
Read More
BTKi-Containing Triplet Active in Relapsed/Untreated Mantle Cell Lymphoma
November 23rd 2020Results from the study were published in Blood and showed that obinutuzumab plus ibrutinib and venetoclax as treatment of patients with relapsed and untreated mantle cell lymphoma achieved high response rates with favorable tolerability.
Read More
Exploring First-line Therapies in Peripheral T-Cell Lymphomas
November 23rd 2020During the Targeted Oncology Case Based Peer Perspectives event, Javier L. Munoz, MD, Hematologist/Oncologist Director, Lymphoma Program Mayo Clinic, discussed the case of 60-year-old patient with peripheral T-cell lymphoma.
Read More
High-Risk MCL Population Represents Unmet Need in Treatment Landscape
October 28th 2020The treatment landscape of mantle cell lymphoma has been enriched with the development of several targeted therapies, but patients considered to have high-risk disease tend to have a worse prognosis, despite the latest development in the field.
Read More
Obinutuzumab Plus DHAP Induces MRD Negativity in Transplant-Eligible Mantle Cell Lymphoma
October 8th 2020Obinutuzumab with dexamethasone plus high-dose cytarabine and cisplatin generated good activity for inducing bone marrow minimal residual disease negativity in patients with mantle cell lymphoma who are eligible for transplant.
Read More